- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03185923
Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe Pneumonia
A Randomized Controlled Trial of Integrated Traditional Chinese and Western Medicine in the Treatment of Severe Community Acquired Pneumonia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Improving the care of patients with community-acquired pneumonia (CAP) has been the focus of many different organizations. Such efforts at improvement in care are warranted, because CAP, especially severe CAP remains the leading cause of death in the world. Despite advances in antimicrobial therapy, rates of mortality due to severe CAP have not decreased significantly since penicillin became routinely available.
traditional Chinese Medicine, has been used for thousands of years in treating pneumonia. To date, it has become popular and widely practiced in many countries around the world. In the past decades, Evidences from both clinicians and patients suggest that there is some beneficial effect of TCM on severe CAP.
At present, there are many therapies available for patients with severe CAP, it is difficult for us to identify the most suitable therapy. Thus, this study aims to compare the efficacy of combination conventional drug and TCM to the conventional drug and placebo, and then determine which one is the better therapy, providing a scientific basis for clinical decision.
This is a multi-center, randomized, controlled trial to compare the efficacy of two therapies for patients with severe CAP. 198 subjects will be randomly assigned to one therapies (conventional drug, and the combination of conventional drug and TCM) for 28 days treatment. After the treatment period, subjects in two arms will be followed up for 12 weeks. The primary outcomes will include treatment failure, and secondary outcomes Time to clinical stability, length hospital stays, in-hospital mortality, SOFA questionnaire, quality of life (CAP-PRO ) and health economics.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: haifeng wang, doctor
- Phone Number: 86-371-66248624
- Email: wangh_f@126.com
Study Contact Backup
- Name: jiangsheng li, doctor
- Phone Number: 86-371-66248624
- Email: li_js8@163.com
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- were aged 18 years to 80 years.
- met severe community-acquired pneumonia criteria (defined by modified American Thoracic Society criteria).
- Syndrome differentiation meets criteria of phlegm-heat obstructing in the lung syndrome, pulmonary stagnation of phlegm syndrome, Pathogenic heat trapping the pericardium syndrome, or Pathogenic depression is taking off syndrome.
Exclusion Criteria:
- Pregnant and lactating women.
- trauma, hematologic malignancies, various solid tumors, and obstetric complications.
- Aspiration pneumonia, fungal pneumonia, HIV related Pneumocystis carinii pneumonia, tuberculosis, Bronchiectasis with infection and pulmonary abscess;
- Dementia, mental disorders and reluctant partners.
- Be discharged from hospital within 2 days or require operation.
- reported severe immunosupression (human immunodeficiency virus infection, immunosuppressive conditions or medications).
- Neuromuscular disorders affecting respiratory motor function.
- Patients with severe cardiovascular,with severe liver and kidney disease.
- Patients who have participated in other clinical studies in the past 4 weeks.
- Patients unwilling to sign informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TCM plus conventional drug
The experimental group will receive three type of TCM inaddition conventional drug according to china CAP guidline 2016.
|
All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome. qingfeijieduhuatan granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days. zaoshihuatanxiefei granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days. qingxinkaiqiao granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days. shenmai injection(Sichuan chuanda west China Pharmaceutical Co., Ltd.),15ml/ ampulla, 10~60ml each time (when needed), for yin exhausted syndrome in 28 treatment days. shenfu injection(Sanjiu Medical & Pharmaceutical Co., Ltd.),10ml/ ampulla, 50~100ml each time (when needed), for yang exhausted syndrome in 28 treatment days. |
Placebo Comparator: TCM placebo plus conventional drug
The control group will receive three type of placebo TCM inaddition conventional drug according to china CAP guidline 2016.
|
All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome. placebo qingfeijieduhuatan granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days. placebo zaoshihuatanxiefei granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days. placebo qingxinkaiqiao granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment failure
Time Frame: up to 28 days.
|
The primary efficacy outcome was the rate of treatment failure, which includes treatment failure that occurred.
|
up to 28 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
time to clinical stability
Time Frame: up to 28 days.
|
Clinical stability
|
up to 28 days.
|
length hospital stays
Time Frame: up to 28 days.
|
length hospital stays will be recorded.
|
up to 28 days.
|
in-hospital mortality
Time Frame: up to 28 days.
|
in-hospital mortality will be recorded.
|
up to 28 days.
|
SOFA questionnaire
Time Frame: Change from baseline SOFA score at day 0、7、14、28 of the treatment phase.
|
Clinical symptom assessment questionnaire of severe CAP
|
Change from baseline SOFA score at day 0、7、14、28 of the treatment phase.
|
CAP -CRO
Time Frame: Change from baseline CAP -CRO score at day 0、7、14、28 of the treatment phase.at week 4, week 8, week 12 of the follow-up phase.
|
CAP doctor reported outcome scale will be used to assess symptoms.
|
Change from baseline CAP -CRO score at day 0、7、14、28 of the treatment phase.at week 4, week 8, week 12 of the follow-up phase.
|
Health economics
Time Frame: up to 28 days.
|
Cost of the treatment phase will be recorded.
|
up to 28 days.
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCM for severe pneumonia
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Community-Acquired Infections
-
GlaxoSmithKlineTerminated
-
GlaxoSmithKlineCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
GlaxoSmithKlineTerminated
-
GlaxoSmithKlineCompleted
-
Indiana UniversityWithdrawnHospital Acquired MRSA | Community Acquired MRSAUnited States
-
Centre Hospitalier Universitaire DijonCompletedCommunity InfectionsFrance
-
Rabin Medical CenterEu Fifth Framework ISTCompletedCross Infection | Community-Acquired InfectionGermany, Israel, Italy
-
Rennes University HospitalCompletedCommunity-Acquired InfectionsFrance
-
BreathTec Biomedical Inc.WithdrawnCommunicable Disease | Respiratory Infection | Infection, Community-Acquired
Clinical Trials on TCM plus conventional drug
-
Henan University of Traditional Chinese MedicineRecruitingChronic Obstructive Pulmonary DiseaseChina
-
Henan University of Traditional Chinese MedicineUnknownPulmonary Disease, Chronic Obstructive | Medicine, Chinese Traditional | Acute Exacerbation
-
Celestino SarduCompletedHeart Failure | Diabetes | Heart Failure NYHA Class II | Heart Failure NYHA Class III
-
Shanghai University of Traditional Chinese MedicineFudan University; Shanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Chest... and other collaboratorsNot yet recruiting
-
Yale UniversityNational Institute on Drug Abuse (NIDA)RecruitingOpioid Use Disorder | Opioid MisuseUnited States
-
The Second Hospital of Hebei Medical UniversityCompletedStroke | Lung DiseasesChina
-
University of AarhusGCP-unit at Aarhus University Hospital, Aarhus, Denmark; Danish Classical Homeopathy... and other collaboratorsCompleted
-
Beijing 302 HospitalUnknownHuman Immunodeficiency Virus | Disorder of Immune ReconstitutionChina
-
Beijing 302 HospitalCompletedHuman Immunodeficiency Virus | Immunodeficiency
-
Pamukkale UniversityCompletedChronic Low-back PainTurkey